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Abstract 
Promoter Hypermethylation of Tumor Related Genes in 
The Progression of Colorectal Neoplasia. 
Promoter hypermethylation causes transcriptional silencing and subsequent 
loss of protein expression of tumor suppressor genes which is commonly found in 
cancer. However, the progression of DNA methylation from normal unmethylated 
and functioning gene to that with aberrant methylation remains elusive. This study 
determined the methylation profiles of primary colorectal cancer and their 
precursor lesion, adenomas. Moreover, we investigated the methylation spread 
phenomenon within the CpG islands of helicase-like transcription factor (HLTF) 
in colorectal cancer by using methylation specific PGR (MSP) and bisulfite 
sequencing. 
Methods: We examined the methylation profiles of 47 sporadic colorectal 
carcinomas, 36 colonic adenomas from patients without cancer and 34 colonic 
biopsies from patients with normal colonic examination. Paired adjacent dysplasia 
tissues were obtained from 17 cancer patients. Colonic tissues were 
microdissected from paraffin embedded sections. DNA was extracted and 
chemically modified by sodium bisulfite to convert all unmethylated cytosine to 
uracil. Promoter hypermethylation in 10 tumor related genes (AFC, ATM, GSTPl, 
vii 
HLTF, MGMT, hMLHl, pl4, pl5, SOCS-1, and TIMP-3) were studied by 
methylation-specific PGR. In addition, we comprehensively examined the 
promoter regions of HLTF in colon cancer and adenoma samples by bisulfite 
sequencing. A total of 59 CpG sites, 42 of them located in promoter region and 17 
of them located in exon-1 region were examined. Normal unmethylated colonic 
tissues and HT29 colorectal cancer cell line was used as control. 
Results: Promoter hypermethylation was detected in more than 40% of 
colonic cancer and adenomas in the following genes: APC’ ATM, HLTF, MGMT, 
hMLHl (p<0.0001 vs. normal). Low level of methylation was detected in pl4, 
pl5 and TIMP-3 whereas no methylation was detected in GSTPl and SOCS-1. 
The frequencies of methylation were comparable between (i) tumors and 
adenomas, (ii) advanced and non-advanced adenoma. Concurrent methylation in 
>3 genes was found in 66.7% adenomas and 68.1% cancers but not in normal 
colonic tissues. There was no significant association between promoter 
hypermethylation and clinicopathological characteristics of cancer. Further 
sequencing of 59 CpG sites within HLTF gene of colon cancer found that 90.2% 
of CpG sites were methylated in the promoter region whereas 82.5% of CpG sites 
were methylated in exon-1 region. For colonic adenoma, 86.2% and 25.8% of 
CpG sites were methylated in the promoter region and exon 1 respectively. 
viii 
Methylation density of promoter in both adenoma and carcinoma were 
significantly higher than unmethylated colonic samples (<8%), (p=0.006 and 
p=0.009). There was a progressive increase in methylation density of exon-1 
region from unmethylated samples to adenoma (p=0.008) and from adenoma to 
carcinoma (p=0.016). 
Conclusion: This study demonstrated the frequent methylation in colonic 
cancers and their precursor lesion, adenoma. Identification of aberrant 
methylation in the precursor lesions may implicate higher oncogenic potential of 
these intermediate lesions and determining epigenetic profile may be a useful tool 
in the early detection of cancer. Furthermore, spreading of CpG sites methylation 
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1.1 Molecular Biology in Cancer Development 
1.1.1 Cell Cycle and Cancer 
The mammalian cell cycle can be divided into four phases, Gl, S, G2 and M, 
plus a resting state, GO (Figure 1-1). The Gl and G2 phases are the gap between S 
phase (DNA synthesis) and M phase (mitosis), and are very important steps in 
providing additional time for the cell prior to entry into the next phase. The Gl 
phase, which precedes the S phase, is regulated by a critical cellular control 
mechanism influenced by extra cellular conditions such as nutrient availability. 
The cell replicates DNA during the S phase, which is followed by the G2 phase. 
Duplicated DNA will be checked to make sure that it is correctly and completely 
copied during the G2 phase. Finally, the cell physically divides during the M 
phase (mitosis). After that, the cell goes back into Gl phase again. The main and 
only purpose of the cell cycle is to create two identical daughter cells. 
The cell cycle is regulated by many factors, which control the activation and 
termination of the cell cycle; DNA replication and monitoring for damage, 
chromosome separation and cell division, etc. Each step is genetically controlled 
and monitored. Once these genetic regulators are missing or have lost their 
function, an uncontrolled or inappropriately controlled cell cycle will result, 
leading to abnormal cell proliferation, and possibly cancer. (Ewen, 2003) 
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Figure 1-1: The Mammalian Cell Cycle. 
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Four phases of mammalian cell cycle including Gapl, S phase, Gap2 and Mitosis 
(M phase). GO is a quiescent state. The cell will decide whether to continue to 
grow or not. 
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1.1.2 Oncogenes and Tumor Suppressor Genes 
Retroviruses, such as Rous Sarcoma Virus (RSV), transcribe their RNA into 
a DNA intermediate which integrates into the host genome. Insertion of such 
DNA insert triggers replication and initiates uncontrollable cell growth and tumor 
development. Oncogene sequences originating from the host cell are called 
"proto-oncogenes". In normal cells, proto-oncogenes such as c-myc, TGFa and 
cyclin D1 encode proteins with numerous functions, including transcription 
factors, growth factors and cell cycle initiator. However, mutational mechanisms 
including chromosomal translocation, gene amplification and point mutations 
cause them to be over expressed and oncogenic. 
The negative regulators of the cell cycle, the tumor suppressor genes, restrict 
the growth and development of tumors. More than 20 different tumor suppressor 
genes have been identified and most of them directly inhibit the growth signal 
from proto-oncogenes. Some tumor suppressor genes do not restrict the cell 
growth but maintain the quality of replicated DNA and act to correct genomic 
errors in cells. Loss of function of tumor suppressor genes creates a 
microenvironment that externally stimulates tumor development or accelerates the 
progression of benign tumors into malignancy, or favors metastasis. Disruption of 
tumor suppressor gene function may occur in different ways: point mutation, 
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deletion, translocation, protein alteration and sometimes the loss of the entire 
chromosome. Moreover, the expression of tumor suppressor genes can be silenced 
by aberrant methylation without changing their sequence. (Trzepacz & Groden, 
2003) 
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1.1.3 Epigenetic Alteration in Tumor Cells 
Russo et al defined the meaning of epigenetics as "the study of mitotically 
heritable changes in gene function that cannot be explained by changes in DNA 
sequence" (Russo et al., 1996). The main epigenetic modification in humans is the 
methylation of cytosine located within the CpG dinucleotide and about 3-4% of 
all cytosines are methylated in normal human DNA (Esteller & Herman, 2002). 
DNA methylation is initiated and maintained by DNA methyltransferase (DNMT) 
enzyme and can be normally found in four cases: imprinted genes, 
X-chromosome genes in women, germline-specific genes and tissue specific 
genes (Baylin et al., 1998). Over expression of DNMTs may result in aberrant 
methylation of tumor suppressor genes and hence rendering normal cell 
oncogenic (Robertson et al., 1999). In summary, there are five types of aberrant 
methylation observed in tumor cells: transcriptional silencing of tumor suppressor 
genes by CpG island promoter hypermethylation; global genomic 
hypermethylation; loss of imprinting events; epigenetic lack of the repression of 
intragenomic parasites; and the appearance of genetic defects in chromatin-related 
genes (Esteller & Herman, 2002). 
Recent studies showed that the development of a normal unmethylated cell 
to a methylated oncogenic tumor cell is a gradual and progressive procedure 
- 6 -
(Graff et al., 2000). In normal situations, bound proteins protect the DNA 
sequence domain against de novo methylation and unmethylated domains 
maintain their function by active demethylation, which removes the modification 
from DNA (Bird, 2002). However, widespread de novo methylation of CpG 
islands is often found in tumor cells. Moreover, studies showed that the spread of 
methylation in oestrogen receptor (ESRl) gene, which results in gene silencing, 
seems to be initiated by aging (Issa et al., 1994). Although the mechanism is still 
unclear, age-dependent promoter hypermethylation might be the explanation for 
the relationship between cancer and aging. (Figure 1-2) 
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Figure 1-2: CpG Island Hypermethylation during Cancer Development 
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CpG islands in normal cells are usually unmethylated and there are bound 
proteins to protect the DNA sequence domain against methylation spread from the 
adjacent region. As the bound protein is lost and methylation spreads out into 
promoter regions of tumor suppression genes, this may initiate the development of 
cancer. White circles, unmethylated CpG; black circles, methylated CpG. 
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1.2 Colorectal Cancer Development 
The definition of colorectal cancer (CRC) by the World Health Organization 
(WHO) is "a malignant epithelial tumor of the colon or rectum. Only tumors that 
have penetrated through muscularis mucosa into submucosa are considered 
malignant. The presence of scattered Paneth cells, neuroendocrine cells or small 
foci of squamous cell differentiation is compatible with the diagnosis of 
adenocarcinoma." (Hamilton et al., 2000) 
1.2.1 Epidemiology of Colorectal Cancer 
Colorectal cancer is highly associated with personal dietary habits. Several 
reports showed that CRC is related to over consumption of animal protein and fats, 
and insufficient fiber intake (Reddy, 1987; Trock et al, 1990). A western style diet 
(highly caloric food rich in animal fat, combined with a sedentary lifestyle), 
smoking and alcohol habits has made CRC the second most common cancer and 
the third leading cause of cancer related mortality in Hong Kong. Both the 
incidence and mortality rates have shown a continuous increase in recent years 
(Figure 1-3) (Hong Kong Cancer Registry, Hospital Authority, Hong Kong). 
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Figure 1-3: Colorectal Cancer Incidence and Mortality Number in Hong 
Kong 
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Both the incidence and mortality rates have increased in recent years. The 
cancer incidence and mortality has almost doubled in the past 20 years ago. 
(Hong Kong Cancer Registry) 
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1.2.2 Adenoma-Carcinoma Sequence 
It is well recognized that the morphological (Figure 1-4) and histological 
progression of colorectal polyps (or adenoma) to cancer is associated with 
continuous accumulation of oncogene activation, and inactivation of tumor 
suppressor genes. 
1.2.2.1 Hyperplastic (metaplastic) Polyps 
Hyperplastic polyps are commonly found non-adenomatous polyp which 
usually appear in the sigmoid colon and rectum. Hyperplastic polyps are small 
(<5mm) and smooth, with mucosal elevation located at the base of the cell near 
the basement membrane. Their proliferative zone often shows increased cellular 
mitotic activity, which may be mistaken as an adenoma. Hyperplastic polyps are 
usually considered to be non-neoplastic. 
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Figure 1-4: Endoscopic appearance of various stages of colorectal cancer 
development 
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Endoscopic picture of gradual change on colonic epithelium tissue form normal 
to malignant carcinoma. 
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1.2.2.2 Aberrant Crypt Foci (ACF) 
Aberrant crypt focus is the earliest morphological precursor of colorectal 
neoplasia. ACF may play a role in the early step of colorectal cancer development 
since dysplasia is often also present. They consist of abnormally large, darkly 
stained, slightly elevated mucosal crypts, and are usually three times wider in 
diameter than normal crypts. They have oval or slit-shaped lumina rather than 
normal circular lumina of normal mucosa. 
1.2.2.3 Adenomas 
Most colorectal carcinomas develop from ACF through adenomas to 
carcinoma. The histological pattern of adenomas can be divided into tubular, 
villous, tubulovillous lesions and serrated adenomas. Smaller spherical shape and 
pedunculated adenomas usually appear in the tubular type, whereas larger or 
sessile with hair-appearing surface adenomas are seen in the villous pattern. 
Tubulovillous adenomas are an 80%/20% mixture of tubular and villous 
structures. Villous adenomas are usually more advanced lesions because they tend 
to contain areas of high-grade dysplasia. 
Practically all adenomas are dysplastic. However, they can be subdivided 
into three groups: adenomas with low-grade dysplasia, adenomas with high-grade 
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dysplasia and adenomas with invasive cancer. Low-grade dysplasia consists of a 
stratified dysplastic epithelium that retains its columnar shape. The spindle- or 
oval- shaped nuclei tend to remain in the lower part of the epithelial lining. 
High-grade dysplasia is present when the nuclei consistently come to the upper 
part of the epithelial lining with apparent loss of the columnar shape of the cell. 
This is accompanied by cellular or nuclear rounding, increasing the 
nuclear/cytoplasmic ratio, nuclear irregularity, development of cellular 
pleomorphism and heaping up of anaplastic cells. High-grade adenomas 
encompassing invasive cancer appear as intraepithelial carcinoma and 
intramucosal carcinoma. Intraepithelial carcinoma is defined as the presence of 
cytologically malignant cells that do not invade into the surrounding lamina 
porpria. Intramucosal carcinoma in defined as malignant cells that invade through 
the basement membrane of their gland into surrounding lamina porpria up to the 
muscularis mucosae. 
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1.2.2.4 Serrated adenomas 
Serrated adenomas do not have any gross features that allow them to be 
distinguished from ordinary adenomas. They are usually associated with goblet 
cell immaturity, combined features of tubular and villous structures and 
"saw-tooth configuration of hyperplasitc polyp" on low power microscopy, but 
with a dysplastic upper zone surface. They are easily misdiagnosed as 
hyperplastic polyps. (Hamilton et al., 2000) 
Recently, hyperplastic polyp and serrated adenoma progression has been 
suggested to be an alternative route for colorectal carcinogenesis, particularly 
those with micro satellite instability. Notably, acquisition of a B-raf mutation 
appears to be associated with the progression of hyperplastic polyp to serrated 
adenoma, whereas progression to admixed hyperplastic polyp/adenoma is 
predominantly associated with acquisition of a ¥^-ras mutation (Chan et al., 
2003). 
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1.2.2.5 Colorectal Carcinomas 
Histopathological classification of CRC according to WHO tumor 
classification scheme is: 
1. Adenocarcinoma: invasion through the muscularis mucosae into the 
submucosa; 
2. Mucinous adenocarcinoma: more than 50% of the lesion is composed of 
mucin; 
3. Signet-ring cell carcinoma: presence of more than 50% of tumor cells with 
prominent intracytoplasmic mucin; 
4. Small cell carcinoma, 
5. Squamous cell carcinoma, 
6. Adenosquamous carcinoma: unusual tumors showing features of both 
adenocarcinoma and squamous carcinoma; 
7. Medullary carcinoma, 
8. Undifferentiated carcinoma: lack of morphological evidence of 
differentiation beyond the epithelial tumor with variable histological features 
(Hamilton et al, 2000) 
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The tumor's architectural features are evaluated by the histological grading 
system. Grade 1 includes well-differentiated, lesions exhibiting glandular 
structures in >95% of the tumor; grade 2 are moderately differentiated tumors 
having 50-90% glands; grade 3 consist of poorly differentiated tumors, with 
5-50% glands and grade 4 undifferentiated tumors have <5% glands. The less 
differentiate the cells are, the faster they grow and the higher the propensity to 
metastasize. (Fenoglio-Preiser & Noffsinger, 2003; Hamilton et al., 2000) 
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1.2.3 Genetic alterations in CRC 
In the normal colonic surface epithelium there is a constant turnover of cells, 
which lasts about 4-7 days. This equilibrium is regulated by the controlled 
proliferation and the programmed cell death (apoptosis) of the anchored crypt 
cells. Genetically, there are two major pathways that may interrupt the 
equilibrium of the colonic cell life cycle: chromosomal instability (CIN) and 
microsatellite instability (Figure 1-5). Cytogenetic alterations, such as 
chromosome breaks, duplication, rearrangement and deletion, occur changing the 
normal diploid nucleus into an aneuploid one, the pattern is being known as 
chromosomal instability (CIN). The CIN pathway includes mutation of the 
adenomatous polyposis coli {APC) gene, K-ra^, p53 and loss of chromosome 18q 
alleles. Yi-ras mutations involving codons 12, 13 and 61 are frequently found in 
the early stage of sporadic CRC (Vogelstein et al., 1988). Interaction of ¥^-ras and 
the APC gene functions as the "gate keeper" of colorectal neoplasm. Mutation of 
APC and Yi-ras occurs in the very early stage of sporadic colorectal cancer. 
The second pathway is the microsatellite instability (MSI) pathway. There 
are several genes involved in the DNA mismatch repair (MMR) system which in 
turn maintain the quality of replicated DNA and correct genomic errors. 
Mutations of human MutL homologue (hMLHl) gene and hMSH2 are frequently 
-18 -
found in HNPCC patients (Papadopoulos et al, 1994) (Bronner et al., 1994). 
Moreover, epigenetic inactivation of both alleles of hMLHl by promoter 
hypermethylation results in microsatellite instability in sporadic colorectal tumor 
(Herman et al, 1998) (Veigl et al., 1998). 



































































































































































































































































































































1.2.4 Epigenetic alterations in CRC 
There is mounting evidences to show that epigenetic changes, in particular 
gene promoter hypermethylation, plays an important role in tumor suppressor 
gene silencing (Jones & Laird, 1999). Hypermethylation of CpG islands in the 
promoter region of tumor suppressor genes cause transcriptional silencing with 
subsequent loss of protein expression. Several studies have demonstrated the 
presence of gene promoter hypermethylation in various human cancers including 
gastric, bladder and cervical cancers (To et al., 2002), (Chan et al., 2003a), 
(Leung et al., 2001). Moreover, methylated DNA was detected in the serum of 
patients with gastric or head and neck cancers (Lee et al., 2002), 
(Sanchez-Cespedes et al, 2000) as well as in the urine or bodily fluids of bladder 
and prostate cancer patients (Chan et al., 2003a), (Goessl et al., 2000). 
In colorectal cancers, promoter hypermethylation has been reported in the 
helicase-like transcription factor (HLTF) (Moinova et al., 2002), APC (Esteller et 
al., 2000), hMLHl (Kane et al., 1997; Leung et al., 1999), pi6 cell-cycle 
regulator (Herman et al., 1995) and tissue inhibitor of metaUoproteinase-3 
{TIMP-3) (Cameron et al., 1999). Furthermore, concurrent methylation in 
multiple genes, also known as the 'CpG island methylator phenotype (CIMP)’ 
when certain loci are methylated, has been described in colorectal cancer (Toyota 
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et al, 1999). The CIMP is more frequently observed in tumors with proximal 
location, microsatellite instability, and with normal p53 (Shen et al., 2003). 
However, the role of promoter hypermethylation in early stages of colorectal 
carcinogenesis, particularly in adenomas and adjacent non-cancer tissues of 
cancer patients, is less well defined. 
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1.2.5 Staging of Colorectal Cancer 
The most important prognostic factor of colorectal cancer is the tumor 
staging. There are two widely used staging systems for colorectal cancer: the 
TNM classification and the Dukes' staging. TNM staging assesses the individual 
tumor depth (T), regional lymph node stage (N) and distant metastases (M), 
whereas Dukes' staging broadly categorizes tumors into four stages (A to D). The 
details and comparisons between the two staging systems are shown in Table 1-1. 






















































































































































































































































































































































































































































































































1. Epigenetic alteration is involved early in the colorectal carcinogenesis 
pathway. 
2. There is a progressive spread of CpG island methylation in the promoter 
region during colorectal cancer development. 
- 2 5 -
1.4 Aim of Study 
This study aims to determine the comprehensive methylation profiles in 
various stages of colorectal cancer development in order to elucidate the role of 
epigenetic changes in the colorectal carcinogenesis process. Further investigation 
will be performed to find out the pattern of spread of methylation in HLTF, a 
SWI/SNF family gene, during neoplastic transformation. 
-26 -
Chapter 2 
MATERIALS and METHODS 
2.1 Patient Populations 
A total of 117 patients including 47 patients with sporadic colorectal cancer, 
36 patients with colonic adenoma and 34 control subjects with normal 
colonoscopic examination were involved in this study. Additionally, paired 
adjacent dysplastic tissues were selected from 17 cancer patients. These samples 
were likely to represent pre-existing adenomas adjacent to cancerous tissue. The 
patients' demographic and clinico-pathological characteristics including age, sex, 
histology, site of lesions and Dukes' staging of tumors were recorded. Adenomas 
were considered to be an advanced lesion if their sizes were >lcm，contained at 
least 25% of villous component or were associated with high grade dysplasia 
(Sung et al., 2003). All patients gave informed consent for obtaining these 
specimens. 
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2.2 Microdissection and Immunohistochemistry 
Surgically removed colorectal cancer tissues or endoscopically removed 
colonic adenomas were fixed in buffered formalin and embedded in paraffin. Five 
jim thick sections were stained with hematoxylin and regions confirmed to contain 
90% carcinoma, adenoma or intra-epithelial neoplasia were microdissected 
(Leung et al., 2000). Normal endoscopic colonic biopsies taken from patients with 
normal colonoscopy were used as control. All available adenoma and 
adenocarcinoma samples were stained for ATM while representative cases were 
selected for immunohistochemical staining for hMLH-1, MGMT and APC. 
Paraffin sections were dewaxed in xylene and rehydrated in a graded series of 
ethanol. Microwave antigen retrieval was performed in citrate buffer (pH 6.0) for 
10 minutes prior to peroxidase quenching with 3% H2O2 in methanol. Sections 
were then washed in water and then incubated with normal serum for 10 minutes. 
Primary antibodies (AFC:C-20, Santa Cruz, CA, USA; MGMT and ATM, Lab 
Vision, Fremont, CA, USA; and hMLHl, BD Pharmingen, USA) were then 
applied. The antibody dilution and incubation conditions were as: ATM{\:\Q) and 
APC: C-20 (1:400) for 2 hours at room temperature; hMLHl (1:50) and MGMT 
(1:50) overnight at 4°C. Biotinylated second antibody and enzyme conjugate 
(Histostain - Plus Kits, Zymed Laboratories, CA, USA) were incubated for 30 
- 2 9 -
minutes each. DAB was added and incubated until chromogen developed with 
hematoxylin as a counter stain. All washing steps were performed with 
Tris-buffered saline for 10 minutes. 
- 3 0 -
2.3 DNA Isolation and Modification 
2.3.1 DNA Extraction from Microdissected Tissues 
Genomic DNA from microdissected tissue was extracted by QIAamp DNA 
Mini kit (Qiagen, Hilden, Germany). Microdissected tissue was dammed in 200jil 
buffer ATL and 40|LI1 of 20 |ig/ml proteinase K was added into the samples and 
incubated at 55°C overnight or until all tissue had dissolved. DNA was then eluted 
in 70|il TE buffer (lOmM Tris, ImM EDTA, pH 7.5) twice to ensure the 
maximum elution of DNA product. 
2.3.2 DNA Extraction from Frozen Biopsy 
Endoscopic colonic biopsies taken from patients with normal colonoscopy 
and colonic tumors were stored in an autoclaved 2ml screw cap vial, immediately 
grasped frozen in liquid nitrogen and stored at -80°C for later use. 400|il ATL 
buffer and 40)il of 20 |Lig/ml proteinase K was added into the vial directly after 
removal from -80�C and incubated at 55°C overnight. DNA was then extracted 
according to manufacturer's instructions after complete digestion of the tissues. 
DNA was eluted in 70|il TE buffer twice to ensure the maximum elution of DNA 
product. 
-31 -
2.3.3 Bisulfite Modification of DNA 
Purified DNA samples were chemically modified by sodium bisulfite with 
the EZ DNA Methylation kit (Zymo Research, CA, USA), which converted all 
unmethylated cytosines to uracils and left methylcytosines unaltered. Five [d of 
M-Dilution Buffer were added to 1.5[ig DNA, and made up to 50|il with MilliQ 
H2O, and incubated at 37�C for 15 minutes. 100|il of CT Conversion Reagent 
were added to each sample then lightly vortexed and incubated at 50�C overnight, 
covered to avoid light. After the complete conversion of unmethylated cytosines 
to uracils overnight, modified DNA samples will be loaded into spin columns 
provided by the manufacturer, and all cleaning and desulphonation procedures 
were completed by a series of steps involving addition of buffer and 
centrifugation. Modified DNA was finally resuspended in 30|^ 1 TE buffer twice to 
ensure the maximum elution of DNA product. 
- 3 2 -
2.4 Detection of K-ras Mutation 
Two lull of genomic DNA was used for detection of ¥.-ras mutation in codon 
12 and 13 by PGR and DNA sequencing. The 25|al PGR mix contained IX PGR 
buffer (lOmM Tris-HCL, pH8.3, 50mM KCl), 2mM MgCb, 0.25mM each of the 
deoxynucleoside triphosphates (MBI Fermentas, Vilnius, Lithuania), 1 unit of 
AmpliTaq Gold Taq polymerase (Applied Biosystems, Foster City, CA) and 1 |iM 
of each primer (Table 2-1). A l l l bp fragment was amplified with annealing 
temperature of SVC for 30 cycles. Two |li1 PGR product was sequenced using the 
ABI Prism Dye Terminator Cycle Sequencing Kit (Applied Biosystems) in the 
ABI Prism 310 DNA Sequencer (Applied Biosystems). (Figure 2-1) 
- 3 3 -
Table 2-1: PCR primer sequence and annealing temperature (Tm). 
Genes Sequences Tm 
., 5'-ATGACTGAATATAAACTTGT-3' (sense) ^ , 
K-ras 51 
5，-CTCTATTGTTGGATCATATT-3，(antisense)  
- 3 4 -
Figure 2-1: Direct Sequencing of K-my mutation. 
CT CT TGGOCCNT ACNQCCCAC CAG CT C C 绝 ACTNAC CA 
20 30 40 50 
J\ , A f t L 
Normal \ \ A A 
y U l i l i f 
ITNCTTGGCin ACGCC CAC CAG CT CCCAMAC TNACNC/ 
40 50 CodonCodon 70 
13 12 
I GCC ACC 
4 ¥ 4 ^ A 
Mutant A 
MNLmiMMM 
Representative case of direct sequencing result output by ABI Prism 310 DNA 
Sequencer. Two |LI1 PCR product was sequenced by antisense PGR primers; a 
mixed peak of C and T residues is expected in the mutant DNA (red arrow). 
Mutated K-ras shows a G to A mutation at codon 12, thus a C to T change in 
the complement strand. 
-35 -
2.5 Methylation-specific PCR (MSP) 
The bisulfite modified DNA was amplified by using primer pairs that 
specifically amplify either methylated or unmethylated sequences of the target 
genes. A total of 10 tumor related genes were examined, including APC, HLTF, 
hMLHl, ataxia telangiectasia mutated {ATM), glutathione S-transferase PI 
(GSTPl), 0^-methylguanine-DNA methyltransferase (MGMT), suppressor of 
cytokine signaling-1 (SOCS-l), TIMP-3, pl4 and pl5. These genes were 
previously shown to be methylated in cancers. The primer sequences are listed in 
Table 2-2. PCR was performed in 25}il reaction volumes containing IX PCR 
buffer (lOmM Tris-HCL, pH8.3, 50mM KCl), 2mM MgCli, 0.25mM each of the 
deoxynucleoside triphosphates (MBI Fermentas), 5pmol of each primer and 1 unit 
of AmpliTaq Gold Taq polymerase (Applied Biosystem). The condition for 
amplification was: 12 min at 9 5 f o l l o w e d by 38 cycles of denaturing at 95°C 
for 45 sec, 30 sec of annealing (for specific temperatures see Table 2-2) and 1 min 
of extension at 72 °C . CpGenome™ Universal methylated DNA (Chemicon 
International Inc., CA, USA.) was used as positive control, and water was 
included as negative control during amplification. Human gastric cell line, AGS, 
and the human prostate cancer cell line, LNCaP, were used as positive controls for 
SOSC-1 (To et al., 2003) and GSTPl (Lee et al., 1994) methylation respectively. 
- 3 6 -
Twenty |il of PGR products were separated in 10% polyacrylamide gel, which was 
stained with ethidium bromide and visualized under UV light (Figure 2-2). 
To test the sensitivity of the MSP, serially diluted genomic DNA extracted 
from paraffin embedded tissues of methylated cancer was examined for every pair 
of MSP primers. The lowest detection limit for all primers in the detection of 
methylated DNA extracted from paraffin section was 0.1 |ig whereas the lowest 
detection limit for in vitro methylated control was 0.01 |ag. (Figure 2-3) 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2-3: Sensitivity test of MSP. 
fe 1 ug 0.1 ug 0.01 ug 0.001 ug IVD H2O 
jg  
S U M U M U M U M U M U M 
Paraffin DNA 
於 / / / / 》 
methylated 
(IVD) 
The detection limit of DNA extracted from paraffin blocks was 0.1 |ag for 
methylated primers and 0.01 |ag for unmethylated primers (representative case, 
hMLH-1, is shown). In contrast, the detection limit of in vitro methylated DNA 
control (IVD) was 0.01|ag for methylated primers (representative case, HLTF, is 
shown). Marker refers to DNA ladder marker OX174. 
-41 -
2.6 Bisulfite DNA Sequencing 
To investigate the methylation spread in promoter and exon-1 region of 
HLTF, bisulfite DNA sequencing was performed. PGR primers (Table 2-3) were 
designed to amplify the CpG rich region of the HLTF promoter and exon-1 
(nucleotide -462 to +243 from the translational start site; GeneBank accession no. 
NT—005616). The 705bp PGR product was cloned into the pCR 2.1-TOPO vector 
using the TOPO TA Cloning kit (Invitrogen, Carlsbad, CA). Five to six colonies 
were selected and grown in LB overnight at 37°C whilst shaken at 250rpm. 
Plasmid DNA was isolated by QIAprep Miniprep Spin Miniprep Kit (Qiagen) and 
2 |il were sequenced using Ml3 primers and the ABI Prism Dye Terminator Cycle 
Sequencing Kit (Applied Biosystems) in ABI Prism 3100 DNA Sequencer 
(Applied Biosystems). 
‘� 
- 4 2 -
Table 2-3: BisulHte sequencing PCR primer sequence and annealing 
temperature (Tm). 
_ Nucleotide 
Gene Sequences Tm Ref  
position  
-462 5'-GTTTGAGGTAGGGAATTAAA-3' (sense) (Leung et al., 
HLTF 51 
+243 5'-CAAAAATTTCCCAAATCCC-3' (antisense) 2003) 
- 4 3 -
2.7 Statistical analysis 
The frequencies of promoter hypermethylation among colorectal cancers, 
adenomas and normal colonic tissues and the density of methylation spread 
between promoter and exon-1 of HLTF gene were compared by Kruskal Wallis 
test or X test. The association between clinicopathological characteristics and 
methylation frequencies in individual genes was analyzed by x test or Fisher 
Exact test where appropriate. The correlation of methylation to patients' age was 
compared by Kendall's tau-b test for the non-parametric correlations. All 
statistical analyses was performed with SPSS software (version 11.0, SPSS Inc) 
and a value of j9<0.05 was considered to be statistically significant. 
- 4 4 -
Chapter 3 
RESULTS 
3.1 Promoter Hypermethylation of Tumor Related Genes 
in the Progression of Colorectal Neoplasia 
3.1.1 Clinico-Pathological parameters 
The baseline characteristics of patients with cancers and adenomas are shown 
in Table 3-1. Among the 47 colorectal cancers, 23 (48.9%) were proximal to the 
splenic flexure and 13 (27.7%) were Duke's C in staging. Of the 36 colonic 
adenomas, 17 (46.2%) were considered to be advanced adenoma. 
Table 3-1: Patients' characteristics 
Normal Adenoma Carcinoma  
|n=34) |n-36) 
i H i i i p i ^ ^ l l l l l i i l l l H i l l l l l l i l l l l l l i l i l H I i H I i i 
Male 17 (50%) 23 (63.9%) 16 (34.0%) 
Proximal location N/A 19 (52.8%) 23 (48.9%) 
Size of adenoma 
< 1cm 25 (69.4%) 
> l c m N/A 11 (30.6%) 博 A 
Histology of adenoma 
Tubular N/A 20 (55.6%) N/A 
Villous 16(44.4%) 
Dysplasia 
Low grade N/A 28 (77.8%) N/A 
High grade 8 (22.2%) 
Dukes' stage 
A N/A N/A 17 (36.2%) 
B 17 (36.2%) 
^ J 13 (27,7%) 
N/A = not applicable 
- 4 6 -
3.1.2 Frequencies of Promoter Hypermethylation in Colorectal 
Cancers, Adenomas and Normal Colonic Tissues 
The frequencies and patterns of promoter hypermethylation of each 
individual gene are shown in Figures 3-1 and 3-2 respectively. As shown in Figure 
3-1, three differential methylation patterns were noted. The first pattern was 
detected in HLTF, hMLHl, MGMT, APC and ATM in which promoter 
hypermethylation was frequently detected in colorectal cancers and adenomas. It 
was noted that more than 40% of colorectal cancers and adenomas demonstrated 
promoter hypermethylation in these loci, and the methylation frequencies were 
significantly higher in cancers or adenomas than in normal colonic tissues 
(p<0.001). However, there was no significant difference in methylation 
frequencies between tumors and adenomas in these loci. The second pattern was 
seen i n p l 4 , p l 5 and TIMP-3 in which promoter hypermethylation was detected at 
a very low frequency (<10%). There was a significant difference in frequency of 
pJ4 methylation between colorectal cancers, adenomas and normal colonic tissues 
(p=0.037). The third pattern was detected in SOSC-1 and GSTPl in which there 
was no methylation detected. 
- 4 7 -
Figure 3-1: Methylation frequency of colorectal cancers，adenomas and 
normal colonic tissues. 
100% •Nornial 
90% - p < 0.001* •Adenoma 
, , • Carcinoma 




5 0 % - • 
4 0 % - 厂 
3 0 % -
p = 0.037 * 
20% -广 I 1 
1�% r - � J rH rl 
Qo/o If I I • I n • I I 1 i ^ i 11 I • I 1 • 丨 
HLTF hMLH-1 MGVIT APC ATM GSTPl pl4 pl5 SOCS-1 TIMP-3  
Methylation of HLTF, hMLHl, MGMT, APC and ATM was more frequently 
detected in cancers (p<0.001) and adenomas (p<0.001) than in normal tissues. 
There was also a significant difference in the frequency of pl4 methylation 
between cancer, adenoma and normal tissue with tumor tissue demonstrating 
the highest methylation frequency (p=0.037). (* Kruskal Wallis Test) 
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Figure 3-2: Methylation patterns in primary colorectal cancers, adenomas 
and normal colonic tissues. 
_ I I t I I I 1 1 i I i 剛 • I I 國 I I I I 
_ 二 m   
urn cm  
m\ cm  
_ — 麵 • m6 M r n  
_ cm ^ M W iH 
_D 衝 
_ i ^二二 = = = cos ' • P Z ： _ 
nm — — — — — cm ^ ^ ^ Z M / K I Z _ _ _ _ 
_ „ , — — C1G  
fm • • ctt B U h I Z ® ! ：  
_ • ~ cai • • 
H4t — 一 一 • 二 = 二：== � 
_ M 1~ — • W z S U l l  
刚 ^ ―HiBj 二 cm _ r ! ! t l J I O l I — — — — 
pm i i t l J I O l I " I I = l 3 | D i C Z _ _ _ _ 
F04 •••••• 二 cm H Z ^ ^ ^ B H H^  
m ••！!3BBII 二 cm 
剛 •B tZdHl I二二二 — ⑶ 
冊 h g Q g i — • z z z • z Q l B U z — — — _ 
_ 二 = • i i z ^ H i j i :  
剛 cm ； 
FIO • • • • • t l = 二 C36 ； = = _ = 
Pii r T ^ M j j j j j ^ r i C3? B l d Z ^ B Z I Z 
i n i n H I U l j l ^ — ~ am — — — 
P14 • • — — J i o© • I I I T ^ • 
Fie m i t r i i d i i 041 _ 
m H i i ^ ^ ^ B z — 二 ： 二 _ l i U C H i i ^ z 二二 
_ B C B i i B i i 二二=二 • • • Q Z B z i i j b i ： — 辦 D z B i H i : 二 二 = : g f • _ m^  pm ZJKm _ P I Q U ^ j U ^  _ • • • “ cm zimmlJlZ 
m? H ^ M b H I ： 二 • 二 1 1 額 — — j m m p ^ — — — — 
剛•ZI^^HHZI • — I l l i O I I  
ra • t i J I I l O l I . _ I 麵 
1 i ? 二 三 三 三 
m \ I I 1 1 cm — I • I I I I • 
The methylation status of each individual sample is shown in rows. Black 
boxes indicate the presence of methylated DNA sequences whereas white 
boxes indicate unmethylated sequences. N refers to normal colonic tissues, P 
refers to adenomas and C refers to cancer samples. 
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3.1.3 Promoter Hypermethylation in Multiple Genes 
Concurrent methylation in multiple genes was frequently detected in 
colorectal cancers and adenomas (Figures 3-3). The mean number of genes 
methylated in colorectal cancers, adenomas and normal colonic tissues was 3.1, 
3.2, and 0.2 respectively. Concurrent methylation of >3 genes was found in 68% 
of cancer and in 66% of adenomas. In contrast, none of the normal colonic tissues 
had concurrent methylation of >3 genes. 
3.1.4 Promoter Hypermethylation in Advanced vs. Non-advanced 
Adenoma 
There was no significant difference in methylation frequencies between 
advanced and non-advanced adenomas in all 10 genes examined (Figure 3-4). 
Concurrent methylation of >3 genes was detected in 76% advanced and 58% 
non-advanced adenoma. 
-50 -
Figure 3-3: Number of genes methylated in colorectal cancers, adenomas and 
normal tissues. 
* * — “ 
I “ I ">=3 
100% - n H • m 
• • •。 
60% 
2 0 % -
0% ‘ ' = ' ‘ ‘ 
Normal (34) Adenoma (36) Cancer (47) 
The number of genes methylated in cancers or adenomas was significantly higher 
than in normal colonic tissues (** p<0.001). 
-51 -
Figure 3-4: Methylation profile between advanced and non-advanced 
adenoma. 
100 / o � • Non-advanced adenoma 
- • Advanced adenoma 
8 0 % -
70% - _ 厂 
60% - ‘ • 
50% - • … p 
40% - • • 
• _ 
30% - • • m 
10% I • • Jj H 
0% - • I “ • I M _i • 1—BL_JIlH_i L.C^B 
HLTF hMLH-1 MGMT APC ATM GSTPl p l4 p l 5 SOCS-1 TIMP-3 
There was no significant difference in methylation frequencies between advanced 
and non-advanced adenoma. 
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3.1.5 Methylation Patterns in Paired Adjacent Dysplastic Tissues 
from Cancer Patients 
The overall methylation frequency of cancer and their adjacent tissues is 
shown in Figure 3-5. It was noted that more than 20% of adjacent dysplastic 
tissues demonstrated methylation in the 5 genes which were frequently methylated 
in cancers {HLTF, hMLHl, MGMT, APC and ATM). The frequency of 
methylation was significantly higher in cancers than in adjacent tissues for the 
ATM gene (p二0.002) but the difference did not reach statistical significance for 
other genes (APC, p=0.271; HLTF, p=0.732; MGMT, p二0.086; and hMLHl, 
p=0.151). Similar to colorectal adenomas, low levels of methylation was detected 
in pl4 and pl5 in adjacent tissues. The mean number of methylated genes was 1.8 
in adjacent dysplastic tissues, and three (18%) samples showed concurrent 
methylation of >3 genes. 
-53 -




90% - p = 0.002 
• Pair-CA 
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70% - • 
60% • • 
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0% . I • I � � • I • I • I ^ j L — u l a 1—B - j 
HLTF hMLH-1 MGMT APC ATM GSTPl pl4 pl5 SOCS-1 TIMP-3 
The methylation frequency of colonic cancers and their paired adjacent dysplastic 
tissues is shown. The frequency of ATM methylation was significantly higher 
(p=0.002) in cancer than in adjacent dysplastic tissues. Otherwise, there was no 
significant difference in methylation frequency between cancer and adjacent 
dysplastic tissues in other genes. 
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3.1.6 Immunohistochemistry 
Protein expressions of ATM, APC, MGMT and hMLHl were examined by 
immunohistochemistry. These genes were studied because they were frequently 
methylated in colorectal cancers and the antibodies were commercially available. 
Reduced protein expressions were observed in adenomas or adenocarcinoma with 
gene promoter methylation, and representative cases are illustrated in Figure 3-6. 
In addition, we examined the expression of ATM in all available cases of 
adenomas (29 cases) and adenocarcinoma (19 cases), and found a significant 
association between promoter hypermethylation of the ATM gene and protein 
expression (p=0.005) (Table 3-2). 
-55 -
Table 3-2: The relationship between protein expression against promoter 
hypermethylation of ATM, 
Score Unmethylated Methylated Total Score scale 
1 1 (7.7%) ~ 6(17.1%) “ 7 1： ^ 5 % 
2 5 (38.4%) 8 (22.9%) ““ 13 2: > 5 - ^ 3 0 % 
3 1 (7,7%) 7(20.0%) 一 8 3: > 3 0 - ^ 6 0 % 
4 — 2 ( 1 5 . 4 % ) 14(40.0o/o厂 16 4: > 6 0 - ^ 9 0 % 
5- 0 (0%) " 4 5: >90% 
Total 13 (100%) 35 (100%) 48 “ 
Chi-square test, p=0.005 
All immunohistochemistry staining was examined and scored 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.1.7 K-ras mutation 
To determine the temporal sequences of promoter hypermethylation and 
Y^-ras mutation in the adenoma-carcinoma transformation process, we examined 
the presence of K -而 mutation in codon 12 and 13 by direct DNA sequencing 
(Benhattar et al., 1993). Whilst K-ras mutation was not detected in any 
non-advanced adenomas, it was noted in 58% of advanced adenomas and 36% of 
cancers. Furthermore, 58% of non-advanced adenoma samples showed presence 
of methylation of three or more genes (Figure 3-7). These findings suggested that 
promoter hypermethylation preceded the development of K-ras mutation in the 
adenoma-carcinoma sequence. However, this study did not show the mutation of 
K-ras was significantly related to CpG methylation phenotype in various stages of 
colorectal cancer development (Table 3-3). 
-61 -
Figure 3-7: Relationship of methylation frequency and hL-ras mutation during 
different stages of colorectal cancer development. 
• K-ras mutation 
100% - • >=3 methylated gene 
81% 
8 0 % 卜 
58% 58% • j j j ^H 
20% - ^ H ^ H 
0% t ^ M | H 0% ‘ ^ ‘ __ 1 
Non-advanced adenoma Advanced adenoma Carcinoma 
The frequency of methylation was not significantly related to K-ras mutation 
in both carcinoma and advanced adenomas. 
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Table 3-3: The relationship between K-ras mutation and methylation 
frequency. 
Advanced adenoma ^ ^^etl|yla”n^requency I 一 
< 3 genes methylated ^ 3 genes methylated Total 
^ . . Normal 1 6 7 
K-ras status ：  
Mutated 3 7 10 
Total 4 13 I 17 
Chi-Square: 0.452 
. „ , Methylation frequency 
All adenoma ‘t^  �i �7 r~i——； 
< 3 genes methylated ^ 3 genes methylated Total 
~ ^ “ N o r m a l 9 17 
Y^-ras status -t t ^  
Mutated 3 7 10 
Total 12 24 | 36 
Chi-Square: 0.792 
Carcinoma Methylation frequency 
< 3 genes methylated ^ 3 genes methylated Total 
二 , , Normal 12 18 W 
K-ras status . , ^ . — — ~ 
Mutated 3 14 17 
Total 15 32 | 47 
Chi-Square: 0.114 
i 1 八 . Methylation frequency 
Adenoma + Carcinoma . ^ , i ‘ , , . , 
‘ < 3 genes methylated ^ 3 genes methylated Total 
~ T T N o r m a l Yl ^ ^ K-ras status ———-; 7 — — ~ Mutated 6 ^ 27 
Total 27 56 | 83 
Chi-Square: 0.164 
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3.1.8 Clinicopathological Correlations with Promoter 
Hypermethylation 
The association between promoter hypermethylation and clinicopathological 
characteristics of cancers is shown in Table 3-4. Methylation of the ^ r M gene was 
more frequent in patients aged >65 years (88.9% vs. 45.5%; p=0.002). On the 
other hand, there was no association between promoter hypermethylation and 
tumor location or staging. 
For colonic adenomas, methylation of the APC gene was more frequent in 
lesions less than 1cm (85.7% vs. 46.7%, p=0.012). Otherwise, there was no 
significant association between promoter hypermethylation and clinico-
pathological characteristics of adenomas (Table 3-5). 
-64 -
Table 3-4: Correlation between methylation in tumor related genes and clinico-
pathological features of colorectal cancer 
HLTF hMLHl MGMT ~APC 
U M p U M p U M p U M p 
Number ^ 25 22 24 2 3 _ 23 24 
Age >65 17 20 0.34 19 18 0.63 17 20 0.18 20 17 0.18 
Male 9 7 0.17 10 6 0.36 8 8 Q.92 6 10 0.26 
Location 
Proximal 10 13 0.90 10 13 0.19 12 11 0.88 14 9 0.11 
Dukes stage 
A 7 10 0.60* 8 9 0.40* S 9 0.73* 7 10 0.58* 
B 6 11 8 9 10 7 10 7 
C I 7 6 I 9 4 I 6 7 1 6 7 
ATM Jl4 JTS TIMP-3 
U M p U M p U M p U M p 
Number 0 4 1 6 4 5 2 ^ 1 
Age >65 5 32 0.002 32 5 0.77 35 2 0.45 34 3 0.28 
Male 5 11 0.36 16 0 0.06 16 0 0.30 13 3 0.20 
Location 
Proximal 6 17 0.67 20 3 0.96 21 2 0.14 22 1 0.17 
Dukes stage 
A 4 13 O J P 15 2 0.72* 16 1 0.54* 16 1 0.50* 
B 3 14 14 3 17 0 14 3 
_ 國 ^ 
* Kruskal Wallis Test 
Since methylation was not detected in SOCS-1 and GSTP1, comparison was not 
performed. 
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Table 3-5: Correlation between methylation in tumor related genes and clinico-
pathological features of colonic adenoma 
HLTF hMLHl MGMT JPC 
U M p U M p U M p U M p 
Number ~ l 2 ^ n 1 4 — 1 4 22 — 15 2 1 — 
Age >65 8 16 1.0 14 10 0.63 10 14 0.63 8 16 0.15 
Male 9 14 0.33 15 8 0.50 9 14 0.97 11 12 032 
Size < 1cm 8 17 0.80 14 11 0.34 9 16 0.59 7 18 0.01 
Location ‘； 
Proximal 7 12 0.64 13 6 034 6 13 034 7 l2 0;54 
Histology 
Tubular 6 14 0.73 11 9 0.50 9 11 0.50 6 14 0.18 
Villous 6 10 11 5 5 11 9 7 
Dysplasia 
Low grade 8 20 0.40 17 11 1.0 10 18 0.68 10 18 0,68 
High grade 4 4 [ 5 3 4 4 5 3 
ATM Jl4 jr5 TIMP-3 
U M p U M p U M p U M p 
Number ~ ~ 9 ^ Y s 1 3 2 4 ^ 3 
Age >65 8 16 0.10 24 0 0.15 23 1 0.06 23 1 0.20 
Male 7 16 0.32 22 1 0.45 22 1 0.09 21 2 0.92 
Size < 1cm 6 19 0.84 25 0 0.13 23 2 0.37 24 1 0.16 
Location 
Proximal 6 13 034 18 1 0.34 17 2 0.91 17 2 0.62 
Histology 
Tubular 5 15 1.0 20 0 0.44 19 1 0.30 19 1 0.57 
Villous 4 12 15 1 13 3 14 2 
Dysplasia 
Low grade 6 22 0.3B 28 0 0.22 26 2 0.21 26 2 0.54 
High grade 3 S : 卜 7 1 6 2 7 1 
Since methylation was not detected in SOCS-1 and GSTPl, comparison was not 
performed. 
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3.2 DNA Methylation Spread within HLTF CpG Island in 
Colorectal neoplasia 
A total of 59 CpG sites within the HLTF gene were analyzed (42 in the 
promoter region and 17 in exon-1) (Figure 3-8). Samples of 21 patients were 
randomly selected from the first part of this study, including 6 cancer patients with 
methylated HLTF, 5 adenoma patients with methylated HLTF, 5 cancers with 
unmethylated HLTF and 5 normal colonic specimens. The colorectal cancer cell 
line HT29 was used as the in vitro methylation control and was found to have 
dense methylation in both the promoter region (90%) and exon-1 region (77.33%). 
In contrast, CpG site methylation was rarely detected (<1.1 %) in both the 
promoter and exon-1 region of normal unmethylated DNA. 
A similarly high methylation density was noted in the promoter region of 
adenoma (86.2%) and carcinoma (90.2%), which were determined to be 
methylated by MSP (p=0.356). There was, however, a significant difference in the 
methylation density in the exon 1 region between MSP-positive adenoma and 
carcinoma (25.8% vs. 82.5%, p=0.016). (Figure 3-9) 
In MSP-negative cancers, methylated CpG sites were rarely detected by 
bisulfite DNA sequencing, which was significantly lower than MSP-positive 
cancers (7.84% in promoter, p=0.006; 2.63% in exon-1, p=0.005). There was no 
difference in methylation density between MSP-negative tumors and normal DNA 
in both promoter (p=0.203) and exon 1 region (p=0.638). 
There was a progressive increase in the methylation density in the promoter 
and exon-1 region with increasing patients age (Figure 3-10). The correlation 
coefficient (R^) was 0.43 in the promoter (p=0.08) and 0.65 in the exon-1 region 
(p=0.065) respectively. 
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Figure 3-9: Average methylation density in promoter and exon-l region of 
HLTF.  
湖 o / o � n - p = 0 . 0 1 6 
• Promoter p-0.009 _^  
90% - —— ^ _ • E»Dn-l 
80% - • • 
70% - | H | 9 
6�% - • • 
50% - • • 
40% - mm Mi 
p=0.008 _ 
30% - 1 S B 國 
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10% - n ^H 
0% ^^ 1 ^ ^ — — ^ I ~ — I M l — — I _ — U H _ _ I 
Normal Tumor (MSP-U) Adenoma Tumor (MSP - M) HT29 
The relationship was compared individually by Mann-Whitney Test. A significant 
difference was found in the methylation density of exon-l region between 
methylated tumor and methylated adenoma (p=0.016), unmethylated tumor DNA 
and methylated adenoma DNA (p=0.008). There was no significant difference in 
the methylation density in the promoter region between normal colonic DNA and 
unmethylated tumor DNA. 
-69 -
Figure 3-10: The relationship between age and methylation density in 
colorectal tumor samples with methylated HLTF. 
100% - 2 • • ^ ^ 
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The pink line indicates correlation between methylation density of exon-1 region 
of HLTF and patients age 0.6546, p二0.065). The blue line shows correlation 





4.1 Methylation is an early event in Colorectal 
Carcinogenesis 
Colorectal adenoma is generally considered to be the precursor lesion of 
colorectal cancer. Though genetic changes associated with the progression from 
adenoma to cancer are well described, the role of epigenetic changes in this 
progression remains poorly defined. To this end, we examined the frequencies and 
patterns of promoter hypermethylation in 10 tumor related genes {APC, HLTF, 
hMLHl, ATM, GSTPl, MGMT, SOCSA, TIMP-3, pi4 a n d p l 5 ) in various stages 
of colorectal cancer development. The chromosomal location and the cellular 










































































































































































































































































































































































































































































































4.1.1 Methylation is frequently detected in both adenoma and 
carcinoma 
The results showed that promoter hypermethylation was frequently detected 
in both cancers and adenomas. Overall, more than 40% of cancers and adenomas 
demonstrated methylation in HLTF, hMLHl, MGMT, APC and ATM. In contrast, 
normal colonic tissues had no or minimal methylation in the promoter regions of 
these loci, suggesting that methylation is a specific phenomenon found only in 
colonic neoplasm. Moreover, methylation tended to cluster in different 
tumor-related genes for different cancers. For instance, although promoter 
hypermethylation of GSTPl was frequently found in prostate (Lee et al., 1994), 
breast, and kidney cancers (Esteller et al., 1998)，methylation was not found in 
any colonic specimens. Moreover, SOCS-l was unmethylated in all colonic 
tissues but was frequently methylated in hepatocellular carcinoma (Yoshikawa et 
al., 2001). The overall methylation frequency was also low i n p l 5 and TIMP-3, 
but frequent methylation of these two genes have been found in leukemia 
(Herman et al., 1996b), kidney, and brain tumor (Bachman et al., 1999). The 
discrepant methylation frequencies in different tumor types might implicate the 
differential role of different tumor-related genes in the carcinogenesis process. 
Distinctive methylation profiles were also noted a in previous study on gastric 
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cancer (Leung et al, 2001). Intuitively, methylation in some genes may confer 
more growth advantages to colonic epithelial cells than to other tissues. 
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4.1.2 Concurrent methylation in multiple genes 
It is interesting to note that the methylation patterns and frequencies are very 
similar in colorectal cancer and their precursor lesion, adenoma. There was no 
significant difference in the methylation frequencies between cancers and 
adenomas for all genes examined. Moreover, concurrent methylation in >3 genes 
was found in 68% of cancer and in 66% of adenomas. This cut off point was 
selected for two reasons. Firstly, the mean number of genes methylated in cancers 
was 3.1. Secondly, none of the normal colonic tissues had concurrent methylation 
in >3 genes. A similar cut-off point has also been used in the definition of CpG 
island methylator phenotype (Toyota et al., 1999). 
4.1.3 Methylation in advanced and non-advanced colorectal 
adenomas 
The methylation frequencies of advanced and non-advanced adenomas were 
comparable (Figure 3-6). In keeping with our finding, Esteller et al. showed that 
the frequency of methylation in the APC gene was similar in small and large 
colonic adenomas (Esteller et al., 2000). Bariol et al also failed to show any 
significant differences in the frequency of methylation between small adenomas, 
large adenomas and cancesr (Bariol et al., 2003). On the other hand, it is reported 
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that methylation is more frequent in adenomas with tubulovillous or villous 
histology (Rashid et al, 2001). These discrepant findings may be related to the 
use of different methylation markers and techniques employed in detecting 
methylation. In the present study, we examined a total of 10 tumor related genes 
whereas the previous two studies examined the methylation status of the MINT 
loci consisting are sites within the genome that are preferentially methylated in 
colorectal tumors (Bariol et al., 2003; Park et al., 2003). Although methylation in 
these loci has been linked to the CpG island methylator phenotype, the functional 
characteristics of these loci remain elusive. Furthermore, we used MSP in this 
study, which is generally considered to be more sensitive than bisulfite-PCR 
followed by restriction enzyme digestion (Herman et al., 1996a). This may also 
explain the relative high frequency of methylation in some of the tumor related 
genes detected in the current study. 
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4.1.4 Relationship between K-ras mutation and methylation 
In this study, K-ras mutation was only detected in advanced colorectal 
adenoma (58%) and cancer (36%). These figures are comparable to the previous 
report on colorectal carcinomas (34%) (Yuen et al., 2002) and large adenomas 
(50%) (Vogelstein et al., 1988). Most available data indicate that K-ras mutations 
occur in the more advanced adenoma stage after APC mutation (Carethers, 2003). 
APC methylation was detected in 68.4% of non-advanced colorectal adenomas 
(Figure 3-4) in which K-ras mutation was not detected. Together, these results 
show that apart from APC mutation, epigenetic alteration takes place earlier than 
K-ras mutation in the adenoma-carcinoma sequence. 
APC gene and K-ras work closely as the “gate keepers" of colonic neoplasia. 
Various mechanisms can lead to alteration of APC, including somatic mutation, 
and LOH (Carethers, 2003). This study also suggests that methylation could be 
considered as another pathway leading to APC alteration in the early stage of 
colorectal carcinogenesis (Esteller et al., 2000). There was no significant 
correlation between APC methylation and ¥^-ras mutation in this study (p=0.082). 
On the other hand, Esteller et al demonstrated a significant correlation between 
MGMT methylation and K-而 mutation in colorectal tumorigenesis. 55% of 
tumor samples with mutant K-ros also had methylated MGMT (p=0.003) (Esteller 
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et al., 2000). Among the 35 samples with K-ras mutation in this study, 19 (54.3%) 
had MGMT methylated but the difference was not significant (p=0.565). This may 
be due to the relatively small sample size of our study subjects. 
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4.1.5 Methylation in adjacent tissues 
We also examined the methylation changes in adjacent dysplastic tissues 
from cancer patients. We noted that the patterns of methylation in adjacent 
dysplastic tissues were similar to that in cancers. Moreover, the methylation 
frequency was comparable to that found in sporadic adenomas of non-cancer 
patients. 
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4.2 DNA Methylation Spread in HLTF gene 
In the second part of this study, further investigations on the methylation 
spread in promoter and exon regions of HLTF, a SWI/SNF family gene, were 
performed. The SWI/SNF family members are a group of chromatin remodeling 
engines and the related proteins have been implicated in many aspects of cellular 
function including maintenance of chromosome stability and proper chromosome 
segregation, recombination, nucleotide excision repair, and transcriptional 
activation or repression. Most SWI/SNF proteins lack specific DNA-binding 
motifs and are thought to contribute to transcriptional access for sequence-specific 
activator proteins. However, HLTF (also called HIP 116a, Zbul, RUSH la, and 
Smarca3) has sequence-specific DNA-binding domains and so can be directly 
targeted to specific promoters (Ding et al., 1996). HLTF suppresses the 
colony-forming ability of //ZrF-deficient, but not //irF-proficient, colon cancer 
cells. (Moinova et al., 2002) 
-81 -
4.2.1 HLTF is Frequently Methylated in Gastrointestinal 
Neoplasm 
In this study, the methylation frequency of HLTF in colorectal cancer and 
adenoma was 57.4% and 66.7%, respectively. This result was comparable to a 
previous report in primary colon cancer (43%) (Moinova et al., 2002). In our 
previous study, HLTF methylation was found in 22% of primary gastric cancer 
(Leung et al., 2003). Hibi et al showed that 3% of esophageal cancer has 
methylated HLTF (Hibi et al., 2003). On the other hand, Moninova et al. found no 
evidence of HLTF gene silencing in lung cancer and breast cancer. Together, these 
data suggest that aberrant DNA methylation in HLTF gene is frequently involved 
in gastrointestinal cancer and thus, is a potential candidate suppressor gene in 
colorectal cancer. However, the mechanisms and the dynamics of the epigenetic 
changes in HLTF gene during the colorectal carcinogenesis remain to be 
elucidated. 
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4.2.2 Methylation Spread Patterns in Cancers and Adenomas 
To clarify the dynamic methylation changes in cancer and adenomas, we 
examined the methylation density of multiple CpG islands located within a 705bp 
region in the promoter and exon-1 region of HLTF by bisulfite sequencing. The 
result showed that there was a progressive increase in methylation density in the 
exon-1 region during colorectal carcinogenesis. Hence, the methylation spread 
was likely initiated in the promoter region and extended in the direction of the 
exon-1 region during colorectal carcinogenesis. 
This finding, however, is different from the previous published study by Yan 
et al. (Yan et al., 2003), which showed that the methylation density change in 
RASSFIA was initiated in the exon-1 region and spread to the promoter region 
during breast cancer development. Nosaka et al. showed that the increase in 
methylation density of the CDKN2A gene within a susceptible CpG island was 
associated with more advanced tumor staging (Nosaka et al., 2000). Whilst all the 
exon regions of their leukemia samples were methylated, a difference in the 
methylation density was demonstrated in the promoter region. 
These discrepant findings may be accounted for the different tissue types as 
well as the different genes examined. These results provide further evidence that 
methylation is a dynamic process and in particular, the pattern of spread may be a 
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tissue- and gene-specific event (Esteller et al, 1998). Further study may be 
necessary to characterize the mechanisms and control of methylation spread in 
cancer progression. We did not examine the expression levels of HLTF because 
the samples were obtained from paraffin blocks and fresh tissue samples for RNA 
and protein expression were unavailable. Moreover, there were no commercially 
available antibodies against HLTF for immunohistochemical staining. 
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4.2.3 Age Dependent Methylation Spread 
Mounting evidence shows that aging might be the single most important risk 
factor for cancer, and age-dependent promoter methylation may be the 
explanation for the relationship between cancer and aging (Jones & Baylin, 2002). 
Issa et al suggested that methylation associated inactivation of the oestrogen 
receptor (ESRl) gene in aging colorectal mucosa could be one of the earliest 
events that cause predisposition to sporadic colorectal cancer (Issa et al., 1994). 
Similar age-dependent methylation changes are demonstrated in MYODl, IGFl 
and M i (Issa, 1999). 
An earlier study of HLTF methylation in colon cancer by Moinova et al. 
found that weak methylation of the HLTF locus was detected in normal tissues of 
older individuals (Moinova et al., 2002). They suggested that HLTF can be 
silenced during aging in some colon cells but age related methylation and HLTF 
gene silencing in cancer are independent events. 
This study also demonstrated that there was an increase in methylation 
density in exon-1 region during aging, though the relationship was not statistically 
significant. The lack of significance is probably owing to the small sample size. 
This trend of increasing methylation density suggested that the spread of 
methylation in HLTF gene may be promoted during aging, which may explain the 
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higher prevalence of advance colorectal neoplasm in the older population. In 
addition to mutation, the accumulation of epigenetic alterations with aging may 




This study suggests the early and specific involvement of promoter 
hypermethylation in the adenoma-carcinoma sequence. Epigenetic changes 
appeared to be detected in apparently trivial non-advanced adenoma even before 
the development of K-nxy mutation. Identification of aberrant methylation in the 
precursor lesions may implicate a higher oncogenic potential of these intermediate 
lesions. Determination of epigenetic profile may be a useful tool in the early 
detection of cancer. 
Moreover, we have demonstrated the pattern of methylation spread in HLTF 
gene in colorectal cancer and their precursor lesions. The distinct direction of 
methylation spread in HLTF gene may also suggest a tissue- and gene-specific 
nature of methylation progression. There is also a dynamic change in the degree 
of methylation density during colorectal carcinogenesis and aging. 
Further study may be necessary to characterize the details of methylation 
spread in various tumor suppressor genes and tissue types, and to explore the 
potential role of detecting aberrant methylation as a surrogate molecular marker in 
risk stratification of colorectal cancer development. 
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